# A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab

> **NCT01743950** · PHASE2 · TERMINATED · sponsor: **University of Wisconsin, Madison** · enrollment: 49 (actual)

## Conditions studied

- Glioma

## Interventions

- **DRUG:** Bevacizumab
- **RADIATION:** PRDR

## Key facts

- **NCT ID:** NCT01743950
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-12-03
- **Primary completion:** 2024-12-24
- **Final completion:** 2024-12-24
- **Target enrollment:** 49 (ACTUAL)
- **Why stopped:** slow accrual
- **Last updated:** 2026-03-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01743950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01743950, "A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01743950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*